Immunosuppressive treatment for IgA kidney disease in stage 3–4
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether immunosuppressive therapy (medicine that calms the immune system) helps people with IgA nephropathy and moderately to severely reduced kidney function. It is intended for adults with confirmed IgA kidney disease who still have significant protein in the urine despite standard blood-pressure kidney protection treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a kidney biopsy showing IgA nephropathy
- You have at least 1.0 gram of protein in your urine per day while on the highest tolerated “RAS” blood-pressure/kidney-protecting medicine
- Your kidney filtering is reduced to about 15–60 ml/min (stage 3 to 4 chronic kidney disease)
- You can safely take immunosuppressive treatment with corticosteroids (not medically contraindicated), and you have not used steroids or other immune-suppressing medicines in the past year
- Your kidney function is stable enough that it’s not being driven by another urgent or changing cause
- You are an adult (18 or older) and your IgA disease is not caused by another underlying condition
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how certain immune cells in blood relate to IgA nephropathy, a kidney condition. It may help doctors understand which patients are likely to do better and guide future care.
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
This trial tests whether mycophenolate mofetil, an immunosuppressant drug, can reduce protein in the urine of people with IgA nephropathy that hasn't responded to other treatments. It aims to help slow down kidney damage.
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
This trial tests whether removing the tonsils (tonsillectomy) plus immune-suppressing therapy can help people with a high-risk form of IgA nephropathy, a kidney disease. It aims to slow down kidney damage and delay the need for dialysis.
This trial enrolls teens and adults with biopsy-proven IgA nephropathy to help doctors learn whether a specific care approach works better for high-quality treatment. It is meant for people whose IgA kidney disease is the primary form (not caused by another illness).
Hear when a new Glomerulonephritis, IGA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.